Table 6 Number of patients per treatment group (Continued or Stopped by June 2021) per time period. Group Zero was determined to be patients who stopped treatment between months 1 and 5, as these were outside normal follow-up. Individual group totals and cumulative totals also included

From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months